Currently Viewing:
American Society of Hematology
Currently Reading
Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
December 07, 2017
Significant Economic Burden Associated With Various AML Treatment Episodes
December 08, 2017
The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life
December 08, 2017
Using Time Spent at Home to Measure End-of-Life Care Quality
December 09, 2017
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
December 10, 2017
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being
December 10, 2017
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10, 2017
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017

Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma

While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.


While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.

Transcript

What progress has been made with CAR T treatments in multiple myeloma?

CAR T treatments are really exciting. They’re at the forefront of what’s being studied in myeloma. They’re not quite ready for prime time, yet, because we still don’t know all of the safety or durability of this treatment.

But one of the exciting things is some of the CAR Ts are actually able to kill myeloma that’s been really resistant, and we’re seeing that in some of the early data presented about the patients who had relapsed and refractory myeloma. And this is really important because some of these patients have no other option. So to have something that really eradicates disease for some patients who were really not able to get a response, that’s really encouraging.

But, like I said before, it’s a therapy that’s not available to everyone just yet. It’s still being studied, particularly for safety and now for efficacy. And once that data is more mature—and I would say that would be maybe in the next 1 to 2 years—we’ll be able to better understand where to position that for a myeloma patient.

What novel treatments in development for multiple myeloma are you keeping an eye on?

We’re looking at ways for myeloma to be attacked, for example, using a different protein on the myeloma surface and tagging that with an antibody or making the antibodies work better. For example, we can maybe activate a T cell and tag that and target it toward an antibody that’s targeting a myeloma cell. We can bring the myeloma cell with the T cell together and make the patient’s own immune system kill the myeloma better.

Or maybe there could be some toxin attached to an antibody, so when the antibody goes to the myeloma cell, it is directly toxic to that cell only. So, you can get specific effects on the myeloma cell. So, really targeting the myeloma cell, itself, with the immune system, is some of the things that we’re looking at.

Some of the other exciting drugs are looking at different intracellular mechanisms, combining known ways of resistance, and unmasking ways to get around that with some intracellular small molecule inhibitors.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up